Cardio Diagnostics released a whitepaper on non-obstructive coronary artery disease (NOCAD), which affects 3-4 million Americans with INOCA. The paper argues that invasive coronary angiography can miss NOCAD because it shows anatomy, not function. It positions the company's AI- and epigenetics-based PrecisionCHD blood test as a low-cost method to identify these patients earlier in primary care. The whitepaper is available for download.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
